Recent-onset Crohn's disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: Results from an analysis of the precise 2 phase III study

Schreiber, S. and Colombel, J. and Panes, J. and Schoelmerich, J. and McColm, J. and Sandborn, W. (2007) Recent-onset Crohn's disease shows higher remission rates and durability of response to treatment with subcutaneous monthly certolizumab pegol: Results from an analysis of the precise 2 phase III study. GUT, 56 (Suppl2). A108-A109. ISSN 0017-5749

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin I
Depositing User: Petra Gürster
Date Deposited: 29 Oct 2020 07:02
Last Modified: 29 Oct 2020 07:02
URI: https://pred.uni-regensburg.de/id/eprint/32947

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.